Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized by repeated episodes of partial or complete upper airway obstruction during sleep. These episodes cause intermittent hypoxia, fragmented sleep, and autonomic fluctuations, triggering oxidative stress, systemic inflammation, sympathetic overactivity, and endothe

Sleep and stroke share a complex, bidirectional relationship. Poor sleep can increase stroke risk, while a stroke itself can disrupt sleep patterns through neurological injury, hospital environments, and post-stroke stress. Understanding how sleep behaves across different age groups throughout the stroke continuum before onset, during admission, an

Lipoprotein(a) [Lp(a)] has become a major focus within cardiovascular medicine due to its strong genetic basis and substantial contribution to residual cardiovascular risk. Elevated Lp(a) is highly prevalent—affecting approximately one in five individuals globally—and is increasingly recognized as a causal, inherited risk enhancer for atherosclerot

Heart failure management traditionally focuses on symptoms, ejection fraction categories, and hemodynamic stability. However, these measures must be interpreted alongside broader factors such as frailty, psychosocial distress, comorbidities, and declining functional status. Heart failure is a chronic, unstable condition where each episode of decomp

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  FDA Approves Diagnostic Test Guiding Targeted Endometrial Cancer Therapy The FDA has approved a new companion diagnostic test to identify patients with microsatellite-stable endometrial carcinoma who may benefit from combination immunothe

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  FDA Approval for Thymidine Kinase 2 Deficiency Treatment The FDA has approved doxecitine and doxribtimine, marking the first approved therapy for thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with symptom onset at

Introduction: Atorvastatin is a potent HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitor that effectively lowers LDL cholesterol and triglycerides, reducing the risk of atherosclerotic cardiovascular events (1). Safe initiation involves verifying baseline liver and renal function, as well as lipid levels, and monitoring for potent

Introduction Prazosin, a selective α₁-adrenergic receptor blocker, is commonly utilized as an adjunct in managing resistant hypertension by relaxing vascular smooth muscle and reducing peripheral resistance (1,2). However, its administration requires caution due to risks of first-dose hypotension, dizziness, and orthostatic symptoms (1,2). Proper m

Watch our recorded webinar and stay ahead this winter season with expert-led insights on COVID-19 and RSV protection. Discover how evolving clinical evidence guides everyday clinical decisions, helping clinicians strengthen prevention strategies, exchange real-world insights, and drive better outcomes for vulnerable patients. MED-QA-mRNA1273-250002